Akkermansia

Akkermansia muciniphila is a Gram-negative, oxygen-avoiding bacterium that belongs to the phylum Verrucomicrobia and lives in the human intestine ^[1]. It was first isolated and described in 2004 by researchers in the Netherlands, who found that it grows on mucin, the gel-forming protein of the gut's mucus layer, using it as its source of carbon and nitrogen; the species is named in honor of the microbiologist Antoon Akkermans ^[1]. It resides in the mucus lining close to the intestinal wall, and in healthy adults it commonly accounts for a small but meaningful share of the gut bacteria ^[1].

Interest in the organism grew when its abundance was found to be inversely linked to body weight and metabolic disease, being reduced in people and animals with obesity and type 2 diabetes ^[2][3]. In mice, giving Akkermansia muciniphila counteracted diet-induced obesity, strengthened the gut barrier, and reduced insulin resistance, effects that depended on the live or suitably prepared bacterium ^[2]. In people, higher natural levels of the microbe were associated with a healthier metabolic profile and with better responses to calorie restriction ^[3]. These findings positioned it as a leading candidate among so-called next-generation probiotics ^[4].

A notable twist came when researchers discovered that pasteurized, or heat-treated, bacteria were at least as effective as live ones in animal models, an effect traced in part to a specific outer-membrane protein of the microbe ^[4]. A first exploratory trial in overweight and insulin-resistant volunteers reported that daily supplementation with the bacterium, especially in pasteurized form, was safe and improved insulin sensitivity and some related markers ^[5]. Regulators in the European Union have since recognized a pasteurized preparation as a novel food, and it is developed and sold as a probiotic supplement rather than as an approved drug; because the organism is sensitive to oxygen, specialized manufacturing is needed to keep it viable ^[4][5].

In the small human studies done so far, both live and pasteurized Akkermansia were well tolerated with no major safety signals. As a relatively new supplement, long-term data is limited. People who are immunocompromised or critically ill should be cautious with any probiotic and consult a doctor.